Cargando…

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus

OBJECTIVE: To examine whether lowering plasma glucose concentration with the sodium-glucose transporter-2 inhibitor empagliflozin improves β-cell function in patients with type 2 diabetes mellitus (T2DM). METHODS: Patients with T2DM (N = 15) received empagliflozin (25 mg/d) for 2 weeks. β-Cell funct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Jobori, Hussein, Daniele, Giuseppe, Adams, John, Cersosimo, Eugenio, Solis-Herrera, Carolina, Triplitt, Curtis, DeFronzo, Ralph A, Abdul-Ghani, Muhammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2018
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328850/ https://www.ncbi.nlm.nih.gov/pubmed/29342295 http://dx.doi.org/10.1210/jc.2017-01838

Ejemplares similares

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes
por: Ali, Ali Muhammed, et al.
Publicado: (2020)

Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
por: Alatrach, Mariam, et al.
Publicado: (2020)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study
por: Solis-Herrera, Carolina, et al.
Publicado: (2013)

Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetes
por: Alatrach, Mariam, et al.
Publicado: (2018)

Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
por: Cersosimo, Eugenio, et al.
Publicado: (2014)

Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control
por: Clarke, Geoffrey D., et al.
Publicado: (2018)

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects
por: Cincotta, Anthony H., et al.
Publicado: (2022)

Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
por: Clarke, Geoffrey D., et al.
Publicado: (2017)

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
por: DeFronzo, Ralph A., et al.
Publicado: (2010)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Pathogenesis of Insulin Resistance in Skeletal Muscle
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2010)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

In Vivo Actions of Peroxisome Proliferator–Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion
por: Eldor, Roy, et al.
Publicado: (2013)

Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

One-Hour Plasma Glucose Concentration and the Metabolic Syndrome Identify Subjects at High Risk for Future Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2008)

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2013)

FRI607 SGLT2 Inhibition Improves Muscle Oxidative Capacity And Its Relationship With Cardiac Performance In Patients With T2D And Heart Failure
por: Qin, Yuejuan, et al.
Publicado: (2023)

Short-Term Exercise Training Improves Insulin Sensitivity but Does Not Inhibit Inflammatory Pathways in Immune Cells from Insulin-Resistant Subjects
por: Reyna, Sara M., et al.
Publicado: (2013)

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
por: DeFronzo, Ralph A.
Publicado: (2009)

Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation
por: Cersosimo, Eugenio, et al.
Publicado: (2014)

Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance
por: Kanat, Mustafa, et al.
Publicado: (2012)

The Relationship Between β-Cell Function and Glycated Hemoglobin: Results from the Veterans Administration Genetic Epidemiology Study
por: Kanat, Mustafa, et al.
Publicado: (2011)

Fasting Versus Postload Plasma Glucose Concentration and the Risk for Future Type 2 Diabetes: Results from the Botnia Study
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2018)

Increased lipid availability for three days reduces whole body glucose uptake, impairs muscle mitochondrial function and initiates opposing effects on PGC-1α promoter methylation in healthy subjects
por: Eldor, Roy, et al.
Publicado: (2017)

The Impact of Vitamin D Deficiency on Retinopathy and Hearing Loss among Type 2 Diabetic Patients
por: Bener, Abdulbari, et al.
Publicado: (2018)

Chronic Reduction of Plasma Free Fatty Acid Improves Mitochondrial Function and Whole-Body Insulin Sensitivity in Obese and Type 2 Diabetic Individuals
por: Daniele, Giuseppe, et al.
Publicado: (2014)

Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy
por: Daniele, Giuseppe, et al.
Publicado: (2020)

Minimal Contribution of Fasting Hyperglycemia to the Incidence of Type 2 Diabetes in Subjects With Normal 2-h Plasma Glucose
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2010)

Two-Step Approach for the Prediction of Future Type 2 Diabetes Risk
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2011)

Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
por: Kane, Michael P, et al.
Publicado: (2020)

Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance
por: Chavez, Alberto O., et al.
Publicado: (2009)

Erratum. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813–820
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
por: Triplitt, Curtis, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dtmdd12k3q6kvng27fshlfe6pl